Mounjaro® (tirzepatide) injection may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
Mounjaro® (tirzepatide) injection (mown-JAHR-OH) is an injectable medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).
Do not use Mounjaro® (tirzepatide) injection if:
You can take Mounjaro® (tirzepatide) injection with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. You should change your injection site each week. Do not use the same site for each injection. Your provider will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimen or stop taking Mounjaro® (tirzepatide) injection as prescribed without discussing with your provider first. If you take too much Mounjaro® (tirzepatide) injection, call your healthcare provider or seek medical advice promptly.
In particular, tell your provider if you have a past history of:
Pregnancy registry: There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Mounjaro® (tirzepatide) injection during pregnancy. Pregnant patients exposed to Mounjaro® (tirzepatide) injection and healthcare providers are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.
These serious side effects are rare, but can occur with Mounjaro® (tirzepatide) injection. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.
You are encouraged to report negative side effects of prescription products to the FDA.
Visit fda.gov/medwatch or call 1-800-FDA-1088.
Disclaimer: Ozempic®, WeGovy®, Saxenda® and Victoza® are registered trademarks of Novo Nordisk. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly. Byetta® and Bydureon® are registered trademarks of Amylin Pharmaceuticals. Brightmeds has no affiliation with Novo Nordisk, Eli Lilly or Amylin Pharmaceuticals. The compounded products available as part of our Weight Loss Program are not made by Novo Nordisk, Eli Lilly or Amylin Pharmaceuticals or any company affiliated with Novo Nordisk, Eli Lilly or Amylin Pharmaceuticals.